title: Design and evaluation of self-nanoemulsifying drug delivery system of flutamide.
abstract: Flutamide (FLT) is an antiandrogen drug for the treatment of prostate cancer. It has the drawback of poor water solubility and needs enhancement of its dissolution rate in simulated gastric fluids. Hence, it is prepared as self-nanoemulsifying drug delivery systems (SNEDDS) with an aim to enhance its dissolution rate. The objectives of the study are to develop SNEDDS of FLT and to characterize for particle size, self-nanoemulsification, and dissolution enhancement. Solubility of FLT was determined in various oils, surfactants, and cosurfactants. Sesame oil was selected as an oil phase, Tween 20 as surfactant, and PEG400 as cosurfactant due to their higher solubilization effect. Various formulations were prepared by simple mixing followed by vortexing. From studies, the optimized SNEDDS formulation was composed of FLT (8.04% w/w), sesame oil (24.12% w/w), Tween 20 (53.38% w/w), and PEG400 (14.46% w/w). The selected SNEDDS could be self-emulsified without precipitation upon simple mixing. The mean particle size of the SNEDDS was 148.7 nm and percent drug content was 99.66. The dissolution rate of FLT from SNEDDS was faster and higher in three different dissolution media such as 2% sodium lauryl sulfate (97.85%), simulated gastric fluid (0.1 N HCl containing 0.5% Tween 20) (95.71%), and simulated intestinal fluid (pH 6.8 buffer) (96.21%).
authors: Institute of Pharmaceutical Technology, Sri Padmavathi Mahila Viswavidyalayam (Women's University), Tirupati, Andhra Pradesh - 517 502, India.
authors: Jyothi B
authors: JB
authors: Jeevana
authors: K
authors: K
authors: Sreelakshmi
references: J Colloid Interface Sci. 1996 Dec 25;184(2):433-6
references: 8978545
references: Drug Dev Ind Pharm. 2005 Sep;31(8):785-94
references: 16221613
references: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):75-87
references: 11259834
references: Eur J Pharm Sci. 2002 Jun;15(5):405-15
references: 12036717
references: Pharm Res. 1995 Mar;12(3):413-20
references: 7617530
references: J Clin Pharmacol. 1989 Jun;29(6):554-8
references: 2754024
references: J Pharm Sci. 2002 Feb;91(2):559-70
references: 11835213
references: J Pharm Sci. 1993 Oct;82(10):979-87
references: 8254497
references: Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S93-8
references: 11033431
references: Int J Pharm. 2004 Apr 15;274(1-2):65-73
references: 15072783
references: Pharm Res. 1994 Feb;11(2):301-4
references: 8165192
references: Int J Pharm. 2000 Dec 15;211(1-2):29-36
references: 11137336
references: J Med Chem. 1967 Jan;10(1):93-5
references: 6031711
references: J Pharm Sci. 1999 Apr;88(4):454-8
references: 10187757
references: Pharm Res. 1998 Jan;15(1):11-22
references: 9487541
references: Nat Rev Drug Discov. 2007 Mar;6(3):231-48
references: 17330072
references: Chem Pharm Bull (Tokyo). 2007 Dec;55(12):1713-9
references: 18057745
references: Int J Pharm. 2001 Jan 16;212(2):233-46
references: 11165081
references: J Control Release. 2006 Jan 10;110(2):332-338
references: 16297483
references: Int J Pharm. 2002 Mar 20;235(1-2):247-65
references: 11879759
references: Eur J Pharm Biopharm. 2000 Jul;50(1):179-88
references: 10840200